Table 1.
Chemotherapy group | |
---|---|
Participants (n) | 708 |
Age (years)# | 70.4 ± 6.9 |
Sex (male/female) | 645/63 |
Smoking history (presence/absence/unknown) | 684/20/4 |
Smoking index (pack-years)# | N = 677, 55.3 ± 30 |
Emphysema (presence/absence/unknown) | 326/381/1 |
Performance status | |
0/1/2/3/4 | 226/378/84/16/4 |
Interstitial pneumonia | |
Clinical diagnosis of IIP (IPF/non-IPF/unknown) | 406/294/8 |
HRCT pattern | |
UIP pattern | 275 |
Possible UIP pattern | 243 |
Inconsistent with the UIP pattern | 190 |
History of acute exacerbation (presence/absence/unknown) | 11/689/8 |
Desaturation on exertion (presence/absence/unknown) | 80/418/210 |
%FVC (%)# | n = 441, 88.6 ± 19.14 |
%DLco (%)# | n = 238, 64 ± 22.56 |
KL-6 (U/mL)# | n = 564, 922.8 ± 985.25 |
SP-D (ng/mL)# | n = 406, 135.6 ± 102.9 |
Treatment | |
None | 678 |
Prednisolone | 15 |
Prednisolone + immunosuppressants | 5 |
Pirfenidone | 7 |
NAC | 1 |
Pirfenidone + NAC | 1 |
Pirfenidone + prednisolone | 1 |
Lung cancer | |
Histopathologic type | |
Small cell carcinoma | 216 |
Non-small cell carcinoma | 492 |
Adenocarcinoma | 258 |
Squamous cell carcinoma | 173 |
LCNEC | 17 |
LCC | 9 |
Others | 35 |
EGFR mutation status | |
Negative | 274 |
Positive | 13 |
L858R/deletion 21 | 9/4 |
Not evaluated | 421 |
ALK re-arrangement | |
Negative | 124 |
Positive | 2 |
Not evaluated | 582 |
ALK anaplastic lymphoma kinase, BSC best supportive care, EGFR epidermal growth factor receptor, %DLco percentage of predicted diffusing capacity of the lung for monoxide, %FVC percentage of predicted forced vital capacity, HRCT high-resolution computed tomography, IIP idiopathic interstitial pneumonia, IPF idiopathic pulmonary fibrosis, KL-6 Krebs von den Lungen-6, LCC large cell carcinoma, LCNEC large cell neuroendocrine carcinoma, NAC inhaled N-acetylcysteine, PS eastern cooperative oncology group performance status, SP-D surfactant protein-D, UIP usual interstitial pneumonia.
#Mean ± standard deviation.